Quickfire Updates From Chicago: What’s New for EGFR TKI Refractory and Resistant Non-Small Cell Lung Cancer?

Are you aware of the rapid progress for patients with epidermal growth factor receptor (EGFR) exon 20 insertion-mutated non-small cell lung cancer (NSCLC) and strategies for tackling osimertinib resistance? Credit available for this activity expires: [07/11/23] Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/976634?src=mkm_podcast_addon_976634